Tracking the Clade Ib Mpox Lineage in Central Africa: Real-Time Genomic Surveillance, APOBEC3 Mutations, and Ring Vaccination Deployment

Real-time genomic sequencing and multicenter epidemiological surveillance across the Democratic Republic of the Congo, Rwanda, Burundi, and Uganda reveal how the newly emerged Clade Ib monkeypox virus lineage—characterized by distinctive host APOBEC3 cytidine deaminase mutation signatures—is driving sustained human-to-human transmission across cross-border mining and commercial corridors, triggering targeted ring vaccination with MVA-BN and clinical trials of next-generation mRNA vaccines.

FE
FIRAT Editorial BoardInstitutional Research Desk
Aug 24, 2026
9 min read
Share:
LSH
FIRAT
FIRATLSH
Research & Translation

Tracking the Clade Ib Mpox Lineage in Central Africa: Real-Time Genomic Surveillance, APOBEC3 Mutations, and Ring Vaccination Deployment

KINSHASA, Democratic Republic of the Congo & KIGALI, Rwanda — August 24, 2026 — In a critical phase of global health emergency response and cross-border pathogen intelligence, coordinated genomic surveillance networks across Central and Eastern Africa have mapped the micro-evolutionary trajectory and transmission dynamics of the Clade Ib monkeypox virus (MPXV). First identified in the mining center of Kamituga in South Kivu province, Democratic Republic of the Congo (DRC), and subsequently detected across contiguous border corridors in Burundi, Rwanda, Uganda, and Kenya, Clade Ib represents a distinct epidemiological shift from historical zoonotic patterns toward sustained, efficient human-to-human transmission.

Coordinated by the , the , the Institut National de Recherche Biomédicale (), the Rwanda Biomedical Centre (), and the Coalition for Epidemic Preparedness Innovations (), real-time whole-genome sequencing (WGS) confirms that Clade Ib isolates exhibit an accelerated accumulation of APOBEC3-mediated cytidine deaminase mutations. This molecular hallmark confirms continuous human-host replication and adaptation.

Concurrently, the deployment of over 300,000 doses of the 3rd-generation Modified Vaccinia Ankara () vaccine—delivered via targeted ring vaccination of healthcare workers, commercial sex workers, and close household contacts across South Kivu, Goma, Bujumbura, and Rubavu—is establishing an immunological firewall to interrupt transboundary transmission chains.


The Emergence of Clade Ib & Human-to-Human Transmission

Historically, Monkeypox virus—a large, double-stranded DNA orthopoxvirus (~197 kilobases)—has been divided into two primary geographic and phylogenetic clades: Clade I (endemic to the Congo Basin, associated with severe systemic disease) and Clade II (endemic to West Africa, including subclade IIb, which drove the multi-country global outbreak in 2022).

For five decades, Clade I transmission in rural DRC (provinces of Équateur, Tshuapa, Sankuru, and Maniema) was characterized by repeated, primary spillover events from wild mammalian reservoirs (such as Funisciurus and Heliosciurus tree squirrels) into rural forest communities, followed by short, self-limiting chains of household transmission predominantly afflicting children under 15 years of age.

Historical Clade Ia Transmission Pattern (Zoonotic Spillover Model):[Wild Forest Rodents / Squirrels] ──► [Spillover to Children / Hunters] ──► [Short Household Stuttering Chains (R₀ < 1)]
Clade Ib Transmission Pattern (Sustained Human Adaptation Model):[Kamituga Mining Hub / Dense Adult Networks] ──► [Sustained Human-to-Human Chains] ──► [Cross-Border Transit (R₀ ≈ 1.2–1.4)][Cross-Border Regional Corridors: DRC (Goma/Bukavu) ◄──► Rwanda ◄──► Burundi ◄──► Uganda]

In September 2023, clinical surveillance teams in Kamituga—a densely populated gold-mining enclave in South Kivu—identified a surge of febrile rash illnesses among adult commercial sex workers and miners. Unlike traditional Clade Ia presentations, patients exhibited prominent anogenital and mucosal lesions, high rates of secondary bacterial superinfections, and rapid secondary transmission among adult sexual partners.

Over the subsequent twelve months, Clade Ib expanded across the transport corridors of the Great Lakes region, establishing active transmission clusters in Bukavu, Goma, Bujumbura (Burundi), Rubavu/Kigali (Rwanda), Kasese/Kampala (Uganda), and coastal Kenya. The rapid transboundary expansion prompted Africa CDC to declare its first Public Health Emergency of Continental Security (PHECS) on August 13, 2024, followed immediately by the WHO Director-General's declaration of a Public Health Emergency of International Concern (PHEIC).


Genomic Architecture & Mutation Profiles

Whole-genome phylogenetic reconstruction conducted by the INRB, the Africa CDC Pathogen Genomics Initiative (Africa PGI), and international collaborating laboratories revealed that Clade Ib forms a distinct, monophyletic subclade descending from ancestral Clade I lineages.

┌─────────────────────────────────────────────────────────────────────────────┐│                     MPXV CLADE IB GENOMIC MUTATION ARCHITECTURE             │├─────────────────────────────────────────────────────────────────────────────┤│ 1. APOBEC3-MEDIATED HYPERMUTATION SIGNATURE                                 ││    • Host Human Cytidine Deaminase Enzyme (APOBEC3) edits viral genome      ││    • Drives characteristic 5'-TC-3' ──► 5'-TT-3' (and GA ──► AA) transitions││    • Over 80% of all novel single-nucleotide polymorphisms follow this motif │├─────────────────────────────────────────────────────────────────────────────┤│                                      │                                      ││                                      ▼                                      ││ 2. STRUCTURAL GENOMIC ALTERATIONS & OPEN READING FRAME DYNAMICS             ││    • Gene OPG153 (Truncations in immune evasion / surface glycoprotein)     ││    • Conserved core genes (DNA polymerase E9L, Topoisomerase I8L) retained  ││    • Terminal Inverted Repeats (TIRs): Dynamic short tandem repeat variation│├─────────────────────────────────────────────────────────────────────────────┤│                                      │                                      ││                                      ▼                                      ││ 3. DIAGNOSTIC REAL-TIME PCR IMPLICATIONS                                    ││    • Legacy Clade I generic primers encounter silent nucleotide mismatches  ││    • Dual-target assays (C1-specific + Generic MPXV) prevent false negatives│└─────────────────────────────────────────────────────────────────────────────┘

APOBEC3 Enzymatic Editing as an Evolutionary Clock

As a double-stranded DNA virus with proofreading DNA polymerases ($E9L$), poxviruses typically exhibit low basal substitution rates ($~1 \times 10^{-6}$ substitutions per site per year). However, when replicating inside human host lymphocytes and mucosal epithelial cells, the viral genome is attacked by the host's innate apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3 (APOBEC3) family of cytidine deaminases.

APOBEC3 deaminates cytosine to uracil on single-stranded viral DNA intermediates during replication, which are repaired as thymine, generating irreversible $TC \to TT$ or $GA \to AA$ transition mutations. In Clade Ib isolates, more than 85% of all identified point mutations match the APOBEC3 enzymatic motif. This confirms that the lineage has been circulating continuously in human transmission chains since at least mid-2023, without requiring recurring animal reservoir spillover.

Comparative Overview of Mpox Viral Clades

+-----------------------+-----------------------+-----------------------+-----------------------+| Epidemiological &     | Clade Ia              | Clade Ib              | Clade IIb             || Genomic Metric        | (Historical Congo)    | (Emergent Great Lakes)| (Global 2022 Lineage) |+-----------------------+-----------------------+-----------------------+-----------------------+| **Primary Geographic**| Central/Western DRC,  | Eastern DRC, Burundi, | Global (Over 110      || **Endemic Zone**      | Rep. of Congo, CAR    | Rwanda, Uganda, Kenya | non-endemic nations)  |+-----------------------+-----------------------+-----------------------+-----------------------+| **Dominant Mode of**  | Zoonotic spillover    | **Sustained human-to-**| Sustained human sexual|| **Transmission**      | + household contacts  | **human & sexual nets**| networks (MSM focus)  |+-----------------------+-----------------------+-----------------------+-----------------------+| **Primary Age Cohort**| Children (<15 years;  | **Young adults (18–45)**| Adults (20–50 years;  || **Affected**          | >65% of cases)        | & secondary pediatric | >95% male adults)     |+-----------------------+-----------------------+-----------------------+-----------------------+| **APOBEC3 Mutation**  | Low / Sporadic        | **High Enrichment**   | **High Enrichment**   || **Signature**         | (<20% of mutations)   | **(>85% TC->TT SNPs)**| (>90% TC->TT SNPs)    |+-----------------------+-----------------------+-----------------------+-----------------------+| **Typical Lesion**    | Generalized pustular; | **Genital, perianal,**| Predominantly genital, || **Distribution**      | centrifugal (face/limbs)| **oral mucosal & body**| mucosal, perianal     |+-----------------------+-----------------------+-----------------------+-----------------------+| **Observed CFR (%)**  | **3.5% – 5.0%**       | **< 1.0% – 1.5%**     | **< 0.1% – 0.2%**     || (With Basic Care)     | (High pediatric mort.)| (Low adult mortality) | (Extremely low mort.) |\n+-----------------------+-----------------------+-----------------------+-----------------------+\n| **Vaccine Neutraliz.**| High cross-protection | **High neutralization**| High cross-protection |\n| **by MVA-BN Antibodies**| by orthopox antisera| **confirmed in vitro**| verified clinically   |\n+-----------------------+-----------------------+-----------------------+-----------------------+\n```\n\n> [!NOTICE]\n> Rapid diagnostic real-time PCR assays must be continuously updated. Several initial commercial Clade I detection kits exhibited target dropouts because mutations clustered within the target binding regions of legacy primers. The deployment of decentralized sequencing across National Public Health Institutes ensures that diagnostic primers remain fully aligned with circulating Clade Ib variants.\n\n---\n\n## Attributed Statements from Epidemiological Leadership\n\nAddressing the operational response and genomic findings across the Great Lakes region, public health directors and clinical researchers emphasized the imperative of equitable countermeasure access:\n\n> \"The declaration of the Public Health Emergency of Continental Security was a watershed moment for African health sovereignty. With Clade Ib, we are not dealing with an isolated rural illness; we are confronting a highly transmissible lineage that moves across borders via commercial and social corridors. Our continental strategy unites genomic surveillance, laboratory diagnostics, and targeted vaccination to protect vulnerable populations and stop this virus at its source.\"\n> — **Dr. Jean Kaseya**, Director-General, [Africa Centres for Disease Control and Prevention (Africa CDC)](https://africacdc.org/)\n\n> \"When our sequencing teams at INRB first analyzed the Kamituga samples, the high density of APOBEC3-type mutations gave us an unmistakable signal: this virus was adapting to continuous human-to-human transmission. This transition requires us to shift our public health strategy from traditional forest-outbreak containment to active contact tracing, stigmatization reduction, and rapid ring vaccination across urban centers.\"\n> — **Prof. Placide Mbala-Kingebeni**, Head of the Epidemiology and Global Health Division, [Institut National de Recherche Biomédicale (INRB)](https://dndi.org/research-development/portfolio/acoziborole/)\n\n> \"The emergence and spread of Clade Ib in the Democratic Republic of the Congo and neighboring countries is a major global concern. Stopping these outbreaks will require a comprehensive, coordinated response that places communities at the center, backed by equitable access to vaccines, diagnostics, and clinical care. WHO is committed to working hand-in-hand with Africa CDC, national governments, and global partners to end transmission.\"\n> — **Dr. Tedros Adhanom Ghebreyesus**, Director-General, [World Health Organization (WHO)](https://www.who.int/)\n\n> \"In Rwanda, our multi-sectoral response mobilized decentralized RT-PCR testing at all border entry points, digital contact tracing through our primary care network, and targeted vaccination of high-risk populations in border districts. Rapid genomic sequencing allows us to confirm within 24 hours whether a case belongs to Clade Ib, ensuring zero undetected community transmission.\"\n> — **Dr. Sabin Nsanzimana**, Minister of Health, Republic of Rwanda\n\n---\n\n## Cross-Border Containment & Vaccine Strategy Implications\n\nThe containment of Clade Ib has catalyzed an unprecedented deployment of medical countermeasures and operational innovations across Central and Eastern Africa:\n\n```\n┌─────────────────────────────────────────────────────────────────────────────┐\n│                     CLADE IB MULTI-TIER VACCINATION STRATEGY                │\n├──────────────────────────┬──────────────────────────┬───────────────────────┤\n│ TIER 1: RING VACCINATION │ TIER 2: TARGETED OCCUP.  │ TIER 3: TRANSBORDER   │\n│ • Primary close contacts │ • Frontline healthcare   │ • Truck drivers       │\n│ • Sexual partners        │   workers & lab staff    │ • Border immigration  │\n│ • Household members      │ • Sex workers & miners   │ • Internally displaced│\n│   (Administered <4 days) │   in active epicenters   │   camp populations    │\n└──────────────────────────┴──────────────────────────┴───────────────────────┘\n```\n\n### 1. Programmatic Deployment of MVA-BN and LC16m8 Vaccines\nThrough donations from the European Union (HERA), the United States, Japan, and direct procurement by Gavi, the Vaccine Alliance, over **300,000 doses of Bavarian Nordic's MVA-BN** and **KM Biologics' LC16m8** have been deployed:\n* **Dosing Regimen**: MVA-BN is administered as a 2-dose subcutaneous regimen (0.5 mL on Days 0 and 28). In acute crisis settings, single-dose priming is utilized to maximize population coverage, with second doses administered as supplies scale.\n* **Pediatric Off-Label and Adolescent Clearances**: While initially approved for adults aged 18 and older, the WHO Strategic Advisory Group of Experts on Immunization ([SAGE](https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization)) and national regulators (DRC, Rwanda, and Burundi) authorized the emergency use of MVA-BN in children and adolescents at high risk of exposure.\n\n### 2. Next-Generation mRNA Vaccine Clinical Trials (CEPI)\nTo overcome the global supply constraints of cell-culture-propagated vaccinia vaccines, CEPI is co-funding multi-center Phase 1/2 clinical trials of next-generation mRNA mpox vaccine candidates (including Moderna's **mRNA-1769** and BioNTech's **BNT166**). Formulated with lipid nanoparticles encoding key surface antigens ($A29L$, $M1R$, $A35R$, and $B6R$), these mRNA constructs induce high-titer neutralizing antibody titers and robust $CD8^+$ T-cell responses while enabling rapid, modular mass manufacturing.\n\n### 3. Integrated One Health and Cross-Border Disease Surveillance\nUnder the **Joint Emergency Preparedness and Response Action Plan (JEAP)** led by Africa CDC and WHO AFRO, cross-border health protocols have eliminated bureaucratic travel restrictions for diagnostic reagents and mobile sequencing teams. Standardized digital health screening at high-volume border crossings (such as the Goma–Gisenyi border, traversed by over 50,000 individuals daily) allows rapid thermal screening, isolation of rash cases, and immediate epidemiological notification.\n\nBy uniting cutting-edge pathogen genomics with decentralized field epidemiology and targeted immunization, African health authorities and global partners are demonstrating a proactive, science-led blueprint to contain emerging infectious threats.\n\n---\n\n## Primary Sources Cited\n\n* [Nature Medicine: Clade I Mpox Virus Genomic Diversity and Transmission Dynamics in the DRC (Vakaniaki et al., 2024)](https://doi.org/10.1038/s41591-024-03130-x)\n* [The Lancet Global Health: Epidemiological Characteristics of Mpox Virus Clade Ib in the Democratic Republic of the Congo](https://www.thelancet.com/journals/langlo/home)\n* [World Health Organization (WHO): Disease Outbreak News — Mpox Global Situation and Clade Ib Spread](https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON587)\n* [Africa CDC Official Communiqué: Declaration of Public Health Emergency of Continental Security for Mpox Surge](https://africacdc.org/news-item/africa-cdc-and-who-launch-joint-emergency-action-plan/)\n* [PubMed Central / NIH: Genomic Monitoring and Tracking of Mpox Virus Clade Ib in Burundi (Nzoyikorera et al., 2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12639094/)\n* [WHO Guidelines: Clinical Management and Infection Prevention and Control for Mpox](https://www.who.int/publications/i/item/WHO-MPX-Clinical-and-IPC-2024.1)\n* [Gavi, the Vaccine Alliance: Mpox Vaccine Response and Supply Coordination Portfolio](https://www.gavi.org/vaccineswork/how-scientists-are-racing-understand-new-mpox-strain-democratic-republic-congo)\n* [Bavarian Nordic Disclosures: MVA-BN Smallpox and Mpox Vaccine Real-World Effectiveness](https://www.bavarian-nordic.com/)\n* [CEPI: Advancing Next-Generation Vaccine Candidates Against Orthopoxviruses](https://cepi.net/)
Filed Under:#Mpox#Clade Ib#Genomic Surveillance#APOBEC3#Africa CDC#WHO#MVA-BN#Infectious Diseases#Epidemiology#Central Africa

Share this research insight

Help circulate peer-reviewed evidence and institutional briefings.

Share:
FE
Author SpotlightDivision: ReMIT

FIRAT Editorial Board

Institutional Research Desk · Foresight Institute of Research and Translation

The collective editorial and research translation board of FIRAT, synthesising peer-reviewed evidence, policy briefs, and division milestones across our seven foundational research pillars.

Focus:Institutional PolicyResearch StrategyAfrican DevelopmentInnovation
More Research

Related Articles in Life Science and Humanity (LSH)

View all in LSH
LSH
FIRAT
FIRATLSH
Research & Translation

Maternal RSV Immunization Breakthrough: NEJM MATISSE Trial and African Antenatal Care Implementation Prove 81.8% Infant Protection Against Severe Bronchiolitis

LSHAug 24, 2026

Maternal RSV Immunization Breakthrough: NEJM MATISSE Trial and African Antenatal Care Implementation Prove 81.8% Infant Protection Against Severe Bronchiolitis

Pivotal Phase 3 MATISSE trial results published in The New England Journal of Medicine and operationalized across South Africa, Kenya, and The Gambia confirm that the bivalent prefusion F maternal RSV vaccine (RSVpreF) delivers 81.8% efficacy against severe lower respiratory tract illness in infants during their first 90 days of life and 69.4% through 6 months, leveraging transplacental IgG transfer to prevent thousands of pediatric hospitalizations across low- and middle-income nations.

By FIRAT Editorial Board
Phase 3 NEJM Trials Confirm Near-Total HIV Protection with Twice-Yearly Lenacapavir, Triggering 120-Country Generic Access Pacts
LSHAug 22, 2026

Phase 3 NEJM Trials Confirm Near-Total HIV Protection with Twice-Yearly Lenacapavir, Triggering 120-Country Generic Access Pacts

Landmark Phase 3 PURPOSE 1 and PURPOSE 2 trials published in The New England Journal of Medicine demonstrate that twice-yearly subcutaneous lenacapavir provides 100% HIV protection in cisgender women and a 96% incidence reduction in gender-diverse cohorts, catalyzing historic voluntary licensing agreements across 120 high-burden nations.

By FIRAT Editorial Board
Personalised mRNA Cancer Vaccine Achieves Historic Phase 3 Success in Melanoma Trial
LSHAug 20, 2026

Personalised mRNA Cancer Vaccine Achieves Historic Phase 3 Success in Melanoma Trial

The INTerpath-001 Phase 3 trial of intismeran autogene, a personalised mRNA vaccine developed by Moderna and Merck, has met its primary endpoint of recurrence-free survival in over 1,100 patients with high-risk melanoma when combined with pembrolizumab — the first late-stage randomised trial of a personalised cancer vaccine to succeed.

By FIRAT Editorial Board